GlassScriptPhysician profile
Sarah V Mcbee
NPI 1689758054
$5,569.88
in general payments reported to CMS, 2019-2025
32 companies · $463 in 2025
The $463 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,313 · 2020: $975 · 2021: $977 · 2022: $831 · 2023: $545 · 2024: $466 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,474.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $944.85 | 2019-2025 | Evenity, Prolia, Prolia |
| Astrazeneca Pharmaceuticals LP | $744.42 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $724.39 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $401.33 | 2019-2025 | Mounjaro, Kisunla, Jardiance |
| Pfizer INC. | $369.53 | 2019-2024 | |
| Esperion Therapeutics, INC. | $357.19 | 2020-2025 | Nexletol |
| Abbvie INC. | $266.59 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $231.09 | 2021-2025 | |
| Medtronic, INC. | $196.58 | 2024-2025 | Minimed 780g |
| Allergan, INC. | $180.13 | 2019-2020 | |
| Glaxosmithkline, LLC. | $175.35 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $146.25 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3, Eterna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.89 | 2019-2023 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $89.57 | 2019-2023 | |
| Mylan Specialty L.P. | $74.86 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $70.67 | 2023-2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $63.45 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.84 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $58.07 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $45.32 | 2020-2022 | |
| Horizon Therapeutics Plc | $38.54 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.77 | 2022 | |
| Exact Sciences Corporation | $35.09 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $24.52 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $21.18 | 2020 | |
| Nevro Corp. | $20.21 | 2021 | |
| Idorsia Pharmaceuticals US INC | $19.16 | 2022 | |
| Philips North America LLC | $17.35 | 2025 | Vest Therapy Und |
| Linus Health, INC. | $13.84 | 2024 | Core Cognitive Evaluation |
| Sanofi Pasteur INC. | $13.69 | 2019 | |
| Xeris Pharmaceuticals, INC. | $12.18 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Mcbee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.